Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 49 | 0.85 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 11780
Sealed predictions
- TREML2 in dopamine neurons, braak+0.24 (p 0.539) → -0.48 (p 0.186)receipt 11787
Swarm cases
receipt 11787: TREML2 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.748, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.07 (p 0.781, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.429, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.03, sign flips 3; without severely affected donors -0.08 (p 0.748, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TREML2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts